tbuckley/cabot-search huggingface dataset:
927P Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as 2nd line treatment for PD-L1 unselected metastatic head and neck cancer patients
Authors: M. Forster, E. Felip, B. Doger, A. Lopez Pousa, E. Carcereny, P. Bajaj, M. Church, J. Peguero, P. Roxburgh, F. Triebel
Journal: Annals of Oncology (2020)
1807P Real world data on 442 patients (p) with small cell lung cancer (SCLC) treated in the last ten years at Vall d’Hebron Hospital
Authors: N. Saoudi Gonzalez, A. Navarro, G. Villacampa Javierre, A. Garcia-Alvarez, J.D.D. Assaf Pastrana, P. Iranzo, A. Callejo, M.J. Lostes Bardaji, N. Pardo, S. Cedres, A. Martinez-Marti, R. Dienstmann, E. Felip
Journal: Annals of Oncology (2020)
Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database
Authors: Anna-Maria Hoffmann-Vold, Yannick Allanore, Margarida Alves, Cathrine Brunborg, Paolo Airó, Lidia P Ananieva, László Czirják, Serena Guiducci, Eric Hachulla, Mengtao Li, Carina Mihai, Gabriela Riemekasten, Petros P Sfikakis, Otylia Kowal-Bielecka, Antonella Riccardi, Oliver Distler
Journal: Annals of the Rheumatic Diseases (2020)

To identify overall disease course, progression patterns and risk factors predictive for progressive interstitial lung disease (ILD) in patients with systemic sclerosis-associated ILD (SSc-ILD), using data from the European Scleroderma Trials And Research (EUSTAR) database over long-term follow-up.
1625MO ABCB1/P-glycoprotein (Pgp) expression as stratification factor for treatment of patients with non metastatic extremity high grade osteosarcoma: An Italian Sarcoma Group (ISG) multicentric prospective trial (ISG/OS-2)
Authors: E. Palmerini, C. Meazza, A. Tamburini, G. Bisogno, V. Ferraresi, S. Asaftei, G.M. Milano, L. Coccoli, C. Manzitti, R. Luksch, D.M. Donati, M. Serra, R. Bertulli, M. Gambarotti, C. Favre, A. Longhi, P.G. Casali, P. Picci, F. Fagioli, S. Ferrari
Journal: Annals of Oncology (2020)
1411TiP GFPC 06-2018: A multicenter non-randomized phase II study evaluating platinum-pemetrexed-atezolizumab (+/-bevacizumab) for patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutations, ALK rearrangement or ROS1 fusion progressing after targeted therapies
Authors: O. Bylicki, B. Clarisse, J-M. Grellard, A. Swalduz, M. Castera-Tellier, S. Ferlandin, I. Monnet, L. Greillier, R. Descourt, J. Peron, C. Chouaid, R. Gervais
Journal: Annals of Oncology (2020)
685P A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC): Outcomes by prostate-specific antigen (PSA) response
Authors: M. Hussain, C.N. Sternberg, E. Efstathiou, K. Fizazi, Q. Shen, X. Lin, J. Sugg, J. Steinberg, B. Noerby, U. De Giorgi, N. Shore, F. Saad
Journal: Annals of Oncology (2020)
Remote Ischemic Perconditioning for the Treatment of Acute Ischemic Stroke—Reply
Authors: Fernando Pico, Bertrand Lapergue, Pierre Amarenco
Journal: JAMA Neurology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
951P The relationship between overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) in immune checkpoint inhibitor clinical trials of head and neck squamous cell carcinoma (HNSCC): A systematic review and meta-analysis
Authors: X. Wang, M. Ballas, H. Chen, K.F. Bell, A. Slowley, C. Ellis, C. Baccan, D.C. Turner, H. Zhou
Journal: Annals of Oncology (2020)
1312P Chemotherapy followed by immunotherapy compared to reverse sequence in NSCLC with PD-L1 low expression: PFS2 analysis
Authors: M. Brambilla, F. Nichetti, R. Loberfaro, G. Galli, A. De Toma, G. Viscardi, A. Prelaj, R. Ferrara, C. Proto, D. Signorelli, A. Bottiglieri, G. Massa, B. Trevisan, M. Ganzinelli, N. Zilembo, F. de Braud, M.C. Garassino, G. Lo Russo
Journal: Annals of Oncology (2020)
423P Gut microbiome predicts a response after preoperative chemoradiation in rectal cancer patients
Authors: B-S. Jang, J.H. Chang, E.K. Chie, K. Kim, J.W. Park, M.J. Kim, E-J. Song, Y-D. Nam, S.W. Kang, S-Y. Jeong, H.J. Kim
Journal: Annals of Oncology (2020)
1302P Lorlatinib in patients with ALK+ NSCLC treated beyond initial disease progression
Authors: S.I. Ou, B. Solomon, A. Shaw, S.M. Gadgeel, B. Besse, R.A. Soo, A. Abbattista, H. Thurm, F. Toffalorio, R.J. Wiltshire, A. Bearz
Journal: Annals of Oncology (2020)
Analysis of spatial osteochondral heterogeneity in advanced knee osteoarthritis exposes influence of joint alignment
Authors: Sophie Haberkamp, Tamás Oláh, Patrick Orth, Magali Cucchiarini, Henning Madry
Journal: Science Translational Medicine (2020)

Advanced human varus knee osteoarthritis correlates in a location-dependent and site-specific fashion with axial malalignment of the lower limb.
928P Phase I dose-expansion (part II) study of ISU104 (a novel anti-ErbB3 monoclonal antibody) alone and combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Authors: S-B. Kim, B. Keam, S. Shin, Y.S. Chae, S. Seo, K. Park, T.M. Kim, L.C. Park, S-B. Hong, E. Lim, S. Lee, M-J. Ahn
Journal: Annals of Oncology (2020)
710P Phase II trial of lenvatinib (LEN) + pembrolizumab (PEMBRO) for progressive disease after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell (mcc) renal cell carcinoma (RCC): Results by independent imaging review and subgroup analyses
Authors: C-H. Lee, A.Y. Shah, J.J. Hsieh, A. Rao, A. Pinto, M.A. Bilen, A.L. Cohn, C. Di Simone, D.R. Shaffer, R. Girones Sarrio, S. Gunnestad Ribe, J. Wu, E. Schmidt, P. Kubiak, C.E. Okpara, A.D. Smith, R.J. Motzer
Journal: Annals of Oncology (2020)
410P Extent of lymph node (LN) resection and tumour sidedness in operable colon cancer (CC) stage and survival
Authors: P. Simões, A. Faria, G. Fernandes, C. Baptista, B. Costeira, L. Leal-Costa, J. Godinho, J. Moreira-Pinto, C. Gomes, J. Correia, J. Albuquerque, T. Padrão, D. Albergaria, H. Oliveira, L. Mascarenhas-Lemos, M. Casa-Nova, J.A. Teixeira, C. Pulido, R. Maio, J.L. Passos-Coelho
Journal: Annals of Oncology (2020)
1111P Suboptimal real-world (RW) outcomes for BRAF+ metastatic melanoma (MM) patients in 2L therapy (The NOBLE study series)
Authors: A.A. Tarhini, A. Betof Warner, M. Johnson, B. Kang, A. Nakasato, M. Vance, Y-L. Ling, J. Tang, J. Patel
Journal: Annals of Oncology (2020)
Determinants of omalizumab dose–related efficacy in oral immunotherapy: Evidence from a cohort of 181 patients
Authors: Pauline Azzano, Maxime Paquin, Alexandra Langlois, Charles Morin, Guy Parizeault, Jonathan Lacombe-Barrios, Kathryn Samaan, François Graham, Louis Paradis, Anne Des Roches, Philippe Bégin
Journal: Journal of Allergy and Clinical Immunology (2020)
477P Genomically-matched therapy in refractory CRC according to ESCAT
Authors: N. Mulet Margalef, C. Castillo, M. Mosteiro, J. Perez Martinez, I. PAdrol, S. Aguilar, M. Martinez Villacampa, J.C. Ruffinelli Rodriguez, F. Losa, A. Teulé Vega, G. Soler, R. Castany, F. Capdevila, M. Gil-Martin, C. Cuadra, E. Elez, E. Garralda, R. Salazar, R. Dienstmann, C. Santos
Journal: Annals of Oncology (2020)
550P Preclinical characterization of CPL304110 as a potential selective inhibitor of fibroblast growth factors 1/2/3 in solid cancers
Authors: D. Popiel, A. Mikołajczyk, M.M. Skupinska, J. Hucz-Kalitowska, P. Stańczak, N. Piotrkowska, A. Yamani, K. Dubiel, J. Pieczykolan, M. Wieczorek, A. Stanczak
Journal: Annals of Oncology (2020)
1422MO Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study
Authors: K. Yamaguchi, Y-J. Bang, S. Iwasa, N. Sugimoto, M-H. Ryu, D. Sakai, H.C. Chung, H. Kawakami, H. Yabusaki, J. Lee, K. Saito, Y. Kawaguchi, T. Kamio, A. Kojima, M. Sugihara, K. Shitara
Journal: Annals of Oncology (2020)
CN21 Patient and occupational safety in Europe: A survey by the European Oncology Nursing Society
Authors: H. Ullgren, L. Sharp, M.N. Fowler, F. Conceicao, P. Crombez, H. Hálfdánardóttir, A. Khmaladze, D. Protogiros, T.A. Theologia, M. van Klinken
Journal: Annals of Oncology (2020)
532MO A phase Ib study of TQB2450 in combination with anlotinib in patients with advanced solid tumour
Authors: Y. Cheng, H. Cui, C. Wu, Y. Wang, T. Zhang, Y. Xin, J. Xu, Y. Chen, Z. Li, Y. Wang, H. Wei, J. Zhu, T. Du
Journal: Annals of Oncology (2020)
142P Correlation between histological pattern and hotspots EGFR mutations in Moroccan lung adenocarcinoma
Authors: S. Boukansa, S. Bardai, L. Bouguenouch, Z. Benbrahim, N. Mellas, M. Serraj, Y. Ouadnouni, M. Smahi, B. Alami, H. El Fatemi
Journal: Annals of Oncology (2020)
484P Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients: A bi-national AGEO/AIOM/GERCOR/FFCD/FRENCH survey
Authors: D. Basile, C. Gallois, F. Puglisi, T. André, S. Benoist, G. Aprile, C. Lepage, P. Laurent-Puig, M. Di Maio, T. Lecomte, S. Pernot, A. Zaanan, J. Taieb
Journal: Annals of Oncology (2020)
Effect of phosphorus-ion implantation on the corrosion resistance and biocompatibility of titanium
Authors: D. Krupa, J. Baszkiewicz, J.A. Kozubowski, A. Barcz, J.W. Sobczak, A. Biliński, M. Lewandowska-Szumieł, B. Rajchel
Journal: Biomaterials (2002)
1499TiP FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for taxane-pretreated patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy – The phase II/III RAMIRIS study
Authors: S-E. Al-Batran, T.O. Götze, T. Dechow, E. Goekkurt, H. Algül, T. Decker, S. Hegewisch Becker, R.D. Hofheinz, M. Möhler, M. Stahl, P.C. Thuss-Patience, S. Herzer, C. Pauligk, S. Lorenzen
Journal: Annals of Oncology (2020)
364O Intracranial efficacy of entrectinib in patients with NTRK fusion-positive solid tumours and baseline CNS metastases
Authors: T. John, C-H. Chiu, B.C. Cho, M. Fakih, A.F. Farago, G.D. Demetri, K. Goto, R.C. Doebele, S. Siena, A. Drilon, M.R. Patel, S.V. Liu, M-J. Ahn, L. Bazhenova, T.R. Overbeck, J. Nieva, S-W. Kim, L. Veronese, B-M. Day, F. De Braud
Journal: Annals of Oncology (2020)
988P Safety analysis of the run-in phase (1st and 2nd cohort) of the IMMUNIB trial (AIO-HEP-0218/ass) - An open-label, single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced stage HCC
Authors: A. Vogel, D.W. Müller, E. De Toni, G.M. Siegler, J. Siebler, U. Lindig, T. Müller, M. Schultheiss, M. Geißler, B. Krammer-Steiner, A. Reichart, F. Lammert, C. Prause, M. Walker, S-E. Al-Batran, N. Kosic
Journal: Annals of Oncology (2020)
Immunomodulation by systemic administration of human-induced pluripotent stem cell-derived mesenchymal stromal cells to enhance the therapeutic efficacy of cell-based therapy for treatment of myocardial infarction
Authors: Si-Jia Sun, Wing-Hon Lai, Yu Jiang, Zhe Zhen, Rui Wei, Qizhou Lian, Song-Yan Liao, Hung-Fat Tse
Journal: Theranostics (2020)

Rationale: Poor survival and engraftment are major hurdles of stem cell therapy in the treatment of myocardial infarction (MI).We sought to determine whether pre-transplantation systemic intravenous administration of human induced pluripotent stem cell (hiPSC)-derived mesenchymal stromal cells (hiPSC-MSCs) could improve the survival of hiPSC-MSCs or hiPSC-derived cardiomyocytes (hiPSC-CMs) following direct intramyocardial transplantation in a mouse model of MI.Methods: Mice were randomized to undergo intravenous administration of saline or 5×10 5 hiPSC-MSCs one week prior to MI, induced by ligation of the left anterior descending coronary artery.Mice were further assigned to undergo direct intramyocardial transplantation of hiPSC-MSCs (1×10 6 ) or hiPSC-CMs (1×10 6 ) 10 minutes following MI.Echocardiographic and invasive hemodynamic assessment were performed to determine cardiac function.In-vivo fluorescent imaging analysis, immunofluorescence staining and polymerase chain reaction were performed to detect cell engraftment.Flow cytometry of splenic regulatory T cells (Tregs) and natural killer (NK) cells was performed to assess the immunomodulatory effects.Results: Pre-transplantation systemic administration of hiPSC-MSCs increased systemic Tregs activation, decreased the number of splenic NK cells and inflammation, and enhanced survival of transplanted hiPSC-MSCs and hiPSC-CMs.These improvements were associated with increased neovascularization and decreased myocardial inflammation and apoptosis at the peri-infract zone with consequent improved left ventricular function four weeks later.Co-culture of splenic CD4 cells with hiPSC-MSCs also modulated their cytokine expression profile with a decreased level of interferon-γ, tumor necrosis factor-α, and interleukin (IL)-17A, but not IL-2, IL-6 and IL-10.Conclusion: Pre-transplantation systemic intravenous administration of hiPSC-MSCs induced immunomodulation and facilitated the survival of intramyocardially transplanted cells to improve cardiac function in MI.
1379P Real-world (RW) clinical outcomes of patients with metastatic non-small cell lung cancer (mNSCLC) in the United Kingdom
Authors: J. Lester, C. Escriu, S. Khan, E. Hudson, T. Mansy, A. Conn, S. Chan, C. Powell, J. Brock, J. Conibear, L. Nelless, V. Nayar, X. Zhuo, A. Durand, A. Amin, P. Martin, X. Zhang, V. Pawar
Journal: Annals of Oncology (2020)
788P Urachal carcinoma: Large retrospective multicentric GETUG-AFU study
Authors: M. Guerin, E. Colomba-Blameble, C. Miran, T. Herrmann, S. Pericart, D. Maillet, Y. Neuzillet, A. Deleuze, C. Thibault, E. Coquan, C. Dumont, E. Boughalem, D. Borchiellini, B. Mesnard, A. Khalil, G. Baciarello, A. Fléchon, J. Walz, G. Gravis
Journal: Annals of Oncology (2020)
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients
Authors: G. Mazzaschi, R. Minari, V. Ferri, P. Bordi, L. Gnetti, M. Bersanelli, A. Cavazzoni, S. Buti, A. Leonetti, A. Zecca, A. Cosenza, L. Ferri, E. Rapacchi, C. Mori, P.G. Petronini, G. Missale, F. Quaini, M. Tiseo
Journal: Annals of Oncology (2020)
291P Trastuzumab emtansine in HER2-positive metastatic breast cancer after pertuzumab and trastuzumab: TDM1RM Study
Authors: J. Martinez-Garcia, A. Puertes Boix, P. Sanchez Henarejos, M.D. Jimenez Lucas, A. Sanchez Saura, M. Luengo, R. Carrillo Vicente, M.J. Martinez Ortiz, J. Balsalobre, P.D.L.M. de la Morena Barrio, E. Garcia Garre, E. Garcia, G. Marin, E. Garcia Torralba, F. Ayala de la Pena, D. Collado, A. Lopez, T. Quiros, D.A. Sánchez, J.L.A. Romero
Journal: Annals of Oncology (2020)
1750P Clinical course and outcome of COVID-19 in cancer patients: Early results from the “onCOVID-19” study
Authors: V. Di Noia, M. Squadroni, R. Barile, A. D'Aveni, A. Liguori, F. Brena, S. Dalto, D. Di Cintio, M.G. Sauta, G.L. Ceresoli, P. Salvini, G.D. Beretta
Journal: Annals of Oncology (2020)
Author correction to ‘Cardamonin from a medicinal herb protects against LPS-induced septic shock by suppressing NLRP3 inflammasome’ [Acta Pharmaceutica Sinica B 9 (2019) 734–744]
Authors: Zhilei Wang, Guang Xu, Yuan Gao, Xiaoyan Zhan, Nan Qin, Shubin Fu, Ruisheng Li, Ming Niu, Jiabo Wang, Youping Liu, Xiaohe Xiao, Zhaofang Bai
Journal: Acta Pharmaceutica Sinica B (2020)
167MO Longitudinal evaluation of serum assessed non-adherence to tamoxifen (TAM) among premenopausal patients (pts) in the prospective multicenter CANTO cohort
Authors: B. Pistilli, A.R. Ferreira, D. Combarel, A. Paci, J. Havas, C. Pradon, A. Bardet, A. Di Meglio, G. Menvielle, L. Fasse, P.H. Cottu, F. Lerebours, C. Coutant, A. Lesur, N. Chopin, S. Everhard, S. Delaloge, S. Michiels, F. André, I. Vaz Luis
Journal: Annals of Oncology (2020)
882TiP InnovaTV 208: New weekly dosing cohort in the phase II study of tisotumab vedotin in platinum-resistant ovarian cancer
Authors: S. Blank, H. Mahdi, O. Tehrani, S. Ghamande, S. Jain, L. Nicacio, I. Soumaoro, D.M. O'Malley
Journal: Annals of Oncology (2020)
1090P Real-world (RW) clinical outcomes in patients (pts) with locally advanced (LA) or metastatic Merkel cell carcinoma (mMCC) treated in United States (US) oncology clinical practices: Results from SPEAR-Merkel
Authors: C.L. Cowey, F.X. Liu, R. Kim, M. Boyd, N. Fulcher, S. Krulewicz, J. Smith, A. Bhanegaonkar
Journal: Annals of Oncology (2020)
Bacteriophage endolysins as a potential weapon to combat <i>Clostridioides difficile</i> infection
Authors: Shakhinur Islam Mondal, Lorraine A. Draper, R Paul Ross, Colin Hill
Journal: Gut Microbes (2020)

Clostridioides difficile is the leading cause of health-care-associated infection throughout the developed world and contributes significantly to patient morbidity and mortality. Typically, antibiotics are used for the primary treatment of C. difficile infections (CDIs), but they are not universally effective for all ribotypes and can result in antibiotic resistance and recurrent infection, while also disrupting the microbiota. Novel targeted therapeutics are urgently needed to combat CDI. Bacteriophage-derived endolysins are required to disrupt the bacterial cell wall of their target bacteria and are possible alternatives to antibiotics. These lytic proteins could potentially replace or augment antibiotics in CDI treatment. We discuss candidate therapeutic lysins derived from phages/prophages of C. difficile and their potential as antimicrobials against CDI. Additionally, we review the antibacterial potential of some recently identified homologues of C. difficile endolysins. Finally, the challenges of endolysins are considered with respect to the development of novel lysin-based therapies.
729P Prognostic value of PD-L1 status in the primary lesion as a risk factor for developing metastatic disease in localized renal cell carcinoma: A subgroup analysis of the ARCHERY study
Authors: M. Nozawa, S. Tamada, K. Ohba, R. Mizuno, A. Takamoto, C. Ohe, T. Yoshimoto, Y. Nakagawa, T. Fukuyama, N. Matsubara, G. Kimura, Y. Tomita, N. Nonomura, M. Eto
Journal: Annals of Oncology (2020)
Letter in response to article in journal of infection: “Clinical characteristics of 345 patients with coronavirus disease 2019 in Japan: A multicenter retrospective study”
Authors: Daisuke Miyazawa
Journal: Journal of Infection (2020)

We read with great interest the study by Ishii M et al., in which hyperuricemia was deemed a novel risk factor for COVID-related death.1Ishii M. Terai H. Kabata H. Masaki K. Chubachi S. Tateno H. et al.Clinical characteristics of 345 patients with coronavirus disease 2019 in Japan: a multicenter retrospective study [published online ahead of print, 2020 Sep 10].J Infect. 2020; https://doi.org/10.1016/j.jinf.2020.08.052Abstract Full Text Full Text PDF PubMed Scopus (27) Google Scholar In this study, severity was defined as the need for oxygen supplementation. Respiratory failure is indeed the most important pathology that contributes to the severity of COVID-19. Obesity is associated with restrictive breathing patterns and reduced lung volumes and is a risk factor for acute respiratory distress syndrome.2Simonnet A. Chetboun M. Poissy J. Raverdy V. Noulette J. Duhamel A. et al.High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation.Obes Silver Spring. 2020; 28: 1195-1199https://doi.org/10.1002/oby.22831Crossref PubMed Scopus (1404) Google Scholar Furthermore, it is also reported as an independent risk factor for the severity of COVID-19.3Petrilli C.M. Jones S.A. Yang J. Rajagopalan H. O'Donnell L. Chernyak Y. et al.Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study.BMJ. 2020; (369:m1966. Published 2020 May 22)https://doi.org/10.1136/bmj.m1966Crossref PubMed Scopus (1806) Google Scholar,4Docherty A.B. Harrison E.M. Green C.A. Hardwick H.E. Pius R. Norman L. et al.Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study.BMJ. 2020; (369:m1985. Published 2020 May 22)https://doi.org/10.1136/bmj.m1985Crossref Scopus (2099) Google Scholar We have previously reported that the association of hypertension, diabetes, and ethnicities, all of which that correlate to obesity, with the severity of COVID-19 and H1N1 may be confounded by obesity to a considerable extent.5Miyazawa D Why obesity, hypertension, diabetes, and ethnicities are common risk factors for COVID-19 and H1N1 influenza infections [published online ahead of print, 2020 Jun 24].J Med Virol. 2020; https://doi.org/10.1002/jmv.26220Crossref Scopus (10) Google Scholar Hyperuricemia and obesity are known to be significantly correlated. Although multiple regression analysis showed that hyperuricemia is an independent risk factor for COVID-related death, the analysis did not include obesity or body mass index as an explanatory variable. Therefore, to truly show that hyperuricemia is a novel risk factor for COVID-related death, a multiple regression analysis including obesity as an explanatory variable is warranted. None.
Dual-adjuvant effect of pH-sensitive liposomes loaded with STING and TLR9 agonists regress tumor development by enhancing Th1 immune response
Authors: Banu Bayyurt Kocabas, Kubra Almacioglu, Esin Alpdundar Bulut, Gozde Gucluler, Gizem Tincer, Defne Bayik, Mayda Gursel, Ihsan Gursel
Journal: Journal of Controlled Release (2020)
Telemedicine: unseen unknowns
Authors: Nathaniel J T Aspray
Journal: BMJ (2020)

After reading this article and the many Twitter conversations it sparked, I was glad to see that there are many GPs and other community workers who are uneasy with a blanket switch to remote consultation as default.1 I have, however, been intrigued that these conversations have largely taken place around the matter of clinical safety and the “unknown unknowns,” rather …
662P Genomic/genetic testing (GT) patterns for patients with metastatic castrate-resistant prostate cancer (mCRPC): Interim results from a real-world study in Europe (EU5)
Authors: A. Leith, A. Ribbands, A. Gayle, S. Payne, C. McCrea, L. Yang, J. Burgents, S. Ghate
Journal: Annals of Oncology (2020)
1079MO Progression of BRAF mutant CNS metastases are associated with a transcriptional network bearing similarities with the innate PD-1 resistant signature (IPRES)
Authors: P.K.H. Lau, B. Feran, L. Smith, A. Lasocki, R. Molania, K. Smith, A. Weppler, C. Angel, D. Kee, P. Bhave, B. Lee, H.X. Aw Yeang, I. Vergara, D. Kok, K. Drummond, P. Neeson, K. Sheppard, T. Papenfuss, S. Sandhu, G. McArthur
Journal: Annals of Oncology (2020)
1644P Dynamic changes in quality of life and Q-TWiST analysis for Ewing sarcoma patients following anlotinib and irinotecan: A combination of phase Ib and II trial
Authors: W. Guo, L. Xie, J. Xu, J. Gu, X. Tang, K. Sun, D. Shen, Y. Li
Journal: Annals of Oncology (2020)